Published in Tumour Biol on September 25, 2012
The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics (2014) 0.99
Biglycan enhances gastric cancer invasion by activating FAK signaling pathway. Oncotarget (2014) 0.96
Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta (2015) 0.92
Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology. Biochim Biophys Acta (2014) 0.84
Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma. HPB (Oxford) (2016) 0.82
COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis. BMC Cancer (2014) 0.80
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer. PLoS One (2013) 0.80
Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology. FEBS J (2016) 0.76
The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat Rev Urol (2015) 0.76
Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression. Oncotarget (2017) 0.75
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol (2006) 2.81
Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol (2010) 2.79
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol (2003) 2.44
Meningioma. Crit Rev Oncol Hematol (2008) 2.10
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study. Int J Radiat Oncol Biol Phys (2013) 2.04
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer (2009) 1.82
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol (2006) 1.77
Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression. J Clin Oncol (2002) 1.75
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology (2014) 1.58
Glioblastoma in adults. Crit Rev Oncol Hematol (2008) 1.54
Colonic sarcoidosis, infliximab, and tuberculosis: a cautionary tale. Inflamm Bowel Dis (2004) 1.51
Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med (2007) 1.51
Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study. Dig Dis Sci (2012) 1.50
The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res (2008) 1.30
High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma (2008) 1.29
Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab (2006) 1.23
Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer (2002) 1.20
Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med (2007) 1.17
Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol (2007) 1.17
Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer (2007) 1.14
Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc (2012) 1.07
Informed consent as an ethical requirement in clinical trials: an old, but still unresolved issue. An observational study to evaluate patient's informed consent comprehension. J Med Ethics (2013) 1.07
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol (2004) 1.05
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch (2004) 1.05
Adult Wilms' tumor: A monoinstitutional experience and a review of the literature. Cancer (2004) 1.05
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol (2010) 1.04
Target delineation in post-operative radiotherapy of brain gliomas: interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans. Radiother Oncol (2005) 1.03
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist (2009) 1.02
Malignant granular cell tumor of the anal-perianal region and suprarenal hyperplasia: a casual association? Indian J Dermatol (2010) 1.01
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer (2005) 1.01
Oligodendroglioma. Crit Rev Oncol Hematol (2008) 1.01
Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol (2008) 1.00
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol (2004) 1.00
Role of mammography, ultrasound and large core biopsy in the diagnostic evaluation of papillary breast lesions. Oncology (2003) 0.99
Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol (2009) 0.99
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol (2006) 0.99
HEX expression and localization in normal mammary gland and breast carcinoma. BMC Cancer (2006) 0.98
The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opin Investig Drugs (2014) 0.98
Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens. Arch Pathol Lab Med (2010) 0.97
Second-line therapy in advanced biliary tract cancer: what should be the standard? Crit Rev Oncol Hematol (2013) 0.96
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol (2004) 0.96
Proteomic analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation. Proteomics (2006) 0.95
Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era. Anticancer Drugs (2009) 0.94
Portal vein thrombosis after intraportal hepatocytes transplantation in a liver transplant recipient. Transpl Int (2005) 0.93
Primary central nervous system lymphoma. Crit Rev Oncol Hematol (2007) 0.93
Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications. Clin Transplant (2010) 0.93
Differential proteomic analysis of hepatocellular carcinoma. Int J Oncol (2010) 0.92
Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma. J Comput Assist Tomogr (2010) 0.92
Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anticancer Drugs (2009) 0.91
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncol (2015) 0.91
TGF-beta1 genotypes in cirrhosis: relationship with the occurrence of liver cancer. Cytokine (2008) 0.91
Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis (2005) 0.91
Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol (2007) 0.91
Contrast enhanced 4D-CT imaging for target volume definition in pancreatic ductal adenocarcinoma. Radiother Oncol (2008) 0.90
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes (2012) 0.90
MTHFR C677T polymorphism and risk of HCC in patients with liver cirrhosis: role of male gender and alcohol consumption. Alcohol Clin Exp Res (2008) 0.90
Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transpl Int (2007) 0.89
Treatment approaches for primary CNS lymphomas. Expert Opin Pharmacother (2010) 0.89
Galectin-3 expression in non-small cell lung carcinoma. Cancer Lett (2004) 0.89
Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Res Treat (2006) 0.87
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology (2006) 0.87
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer Res (2010) 0.87
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Eur J Cancer (2013) 0.87
Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study. BMC Health Serv Res (2008) 0.87
Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas? J Clin Oncol (2004) 0.87
MRI scoring system including dynamic motility evaluation in assessing the activity of Crohn's disease of the terminal ileum. Acad Radiol (2008) 0.87
The role of CXCR4 in highly malignant human gliomas biology: current knowledge and future directions. Glia (2014) 0.86
Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev (2012) 0.86
Role of tumor associated fibroblasts in human liver regeneration, cirrhosis, and cancer. Int J Hepatol (2011) 0.86
Elevated serum CA 19-9 in hepatic actinomycosis. Scand J Gastroenterol (2005) 0.86
The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil alone. Cancer Invest (2003) 0.86
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer (2010) 0.85
Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system. Crit Rev Oncol Hematol (2012) 0.85
Solitary clival plasmocytomas: Misleading clinical and radiological features of a rare pathology with a specific biological behaviour. Acta Neurochir (Wien) (2013) 0.85
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol (2008) 0.84
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. J Thorac Oncol (2014) 0.84
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. J Thorac Oncol (2015) 0.84
Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol (2008) 0.84
Adjuvant treatment in biliary tract cancer: to treat or not to treat? World J Gastroenterol (2012) 0.83
Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors. Radiother Oncol (2011) 0.83
Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett (2004) 0.83
Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol (2010) 0.83
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Chemotherapy (2011) 0.83
Helicobacter pylori associated antigastric autoantibodies: role in Sjögren's syndrome gastritis. Helicobacter (2004) 0.83
Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys (2010) 0.83
Annular elastolytic giant cell granuloma treated with topical pimecrolimus. Indian J Dermatol Venereol Leprol (2014) 0.82
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol (2011) 0.82
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol (2012) 0.82